Sheila Collins

Sheila Collins, Ph.D., is a Professor in the Department of Cardiovascular Medicine at Vanderbilt University School of Medicine. Her research focuses on biochemical mechanisms regulating body weight, insulin sensitivity, and adipose tissue metabolism, with a particular emphasis on natriuretic peptide signaling and its role in metabolic diseases. Her lab explores how hormones like ANP and BNP influence adipocyte function, energy expenditure, and cardiometabolic health. Recent work highlights the therapeutic potential of targeting salt-inducible kinases, mTOR signaling, and exocytosis pathways to combat obesity and related heart failure.

Her studies integrate molecular biology, pharmacology, and clinical insights to dissect pathways linking cardiac peptides to adipose biology. Key findings include the discovery of novel signaling axes (e.g., PKA-mTORC1) and the role of natriuretic peptide receptors in obesity-associated cardiomyopathy. Preclinical models reveal how manipulating these pathways can mitigate metabolic syndrome and improve cardiovascular outcomes.

Collins’ research also addresses sex differences in metabolic regulation and the impact of chronic conditions like hypercortisolism on adipose tissue redistribution. Her lab maintains a strong translational focus, evaluating drug candidates such as PDE9 inhibitors that modulate cGMP signaling to reduce obesity and cardiometabolic risks. While no formal students are listed, her work has trained numerous postdoctoral researchers and shaped the field of adipose biology.

Labs/Teams: Her research lab at Vanderbilt University Medical Center (VUMC) collaborates with cardiovascular and endocrine specialists to advance therapies for cardiometabolic disorders. Her lab website provides further details on ongoing projects and publications.